Iliad Biotechnologies LLC, of Weston, Fla., and Vanderbilt University Medical Center report that an investigational new drug (IND) application has been filed by the National Institute for Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH) to study the next generation pertussis vaccine BPZE1.